Form 4: PTC Therapeutics Exec Sells Shares Under 10b5-1 Plan

A PTC Therapeutics Executive VP and CLO sold common stock totaling 6,347 shares across multiple transactions in early January 2026, primarily under a 10b5-1 plan.

Summary

• Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT), reported the sale of 6,347 shares of common stock.
• The sales occurred across six separate transactions on January 8 and January 9, 2026.
• Weighted average sale prices ranged from $76.45 to $79.52 per share.
• A total of 5,061 shares were sold pursuant to a Rule 10b5-1 plan, which was adopted by Mr. Boulding on December 4, 2024.
• An additional 1,286 shares were automatically sold to satisfy tax withholding obligations related to the vesting of 3,600 Restricted Stock Units (RSUs) from a January 7, 2022 grant.
• Following these transactions, Mr. Boulding beneficially owns 111,312 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: The transactions are routine insider sales, largely pre-planned under a 10b5-1 plan, and include a 'sell to cover' for tax obligations. This type of filing is generally neutral in sentiment as it does not reflect new information about the company's performance or outlook.

Positives

• The majority of the sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating scheduled transactions rather than a reaction to new, undisclosed information.
• A portion of the sales was specifically for tax withholding obligations related to RSU vesting, which is a routine and expected event for executives.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Key Dates

Recommendation

This Form 4 details routine, pre-planned insider stock sales and tax-related transactions. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

PTC Therapeutics, PTCT, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Common Stock, RSU Vesting